Tanya Brinsden, senior VP of operations at ICON Global Medical Communications and Pubs Hub, Jessica Cherian, VP of content and strategic services at ICON Market Access and Reimbursement, an
More so now than ever, the inclusion of more diverse, and often more relevant, study populations is gathering momentum within the clinical trial community.
Advances in cell and gene science are paving the way for transformative cancer treatments, but there are still many complexities in delivering clinical trials for these therapies.
With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandolimast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo
